百悦泽砍下全球销冠！百济神州：开启跨国药企之路？

Group 1 - The core viewpoint of the article highlights that BeiGene has transitioned from continuous losses to sustained profitability, with clear performance guidance for 2025 and 2026 [1][3][7] - For the fiscal year 2025, the company expects total revenue of 38.205 billion, representing a year-on-year growth of 40.4%, achieving the upper end of its previous revenue guidance of 5.1-5.3 billion USD [4][6] - The projected net profit attributable to the parent company for 2025 is 1.422 billion, marking the company's first anticipated profit for the year [5][6] Group 2 - The company maintains an optimistic outlook for 2026, forecasting total revenue between 6.2-6.4 billion USD, which corresponds to a year-on-year growth of approximately 14-18% [6] - Operating profit for 2026 is expected to be between 700-800 million USD, indicating a significant year-on-year increase of 57%-79% [6]